Newsroom

January 2015

• Press release Jan 27, 2015

  Novartis a enregistré en 2014 une forte augmentation de ses ventes, sa marge et progrès de son pipeline; la transformation du portefeuille concentrera l'entreprise sur ses principales activités

  Hausse du chiffre d'affaires net en 2014, avec une forte augmentation de la marge core[1] Hausse du chiffre d'affaires net de 1% (+3% tcc[1])[2] à USD 58,0 milliards en 2014 (-2%, +4% tcc au T4)…
• Press release Jan 27, 2015

  Novartis erzielt 2014 solide Umsatzsteigerungen, höhere Margen und Fortschritte in der Pipeline; mit der Umgestaltung des Portfolios fokussiert sich das Unternehmen auf führende Geschäftsbereiche

  Wachstum des Nettoumsatzes im Jahr 2014 - mit starker Erhöhung der Kerngewinnmarge[1] Der Nettoumsatz steigt 2014 um 1% (+3% kWk[1])[2] auf USD 58,0 Milliarden (4. Quartal: -2%, +4% kWk) Das…
• Press release Jan 23, 2015

  Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US

  With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
• Press release Jan 23, 2015

  Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera

  Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1]  Clinical data show Jakavi® (…
• Press release Jan 21, 2015

  Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients

  Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
• Press release Jan 19, 2015

  Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients

  Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
• Press release Jan 12, 2015

  Novartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patients

  Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
• Press release Jan 08, 2015

  Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA

  Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5]  US trials for QVA149 demonstrated significant…
• Press release Jan 07, 2015

  Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee

  Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
• Press release Jan 07, 2015

  Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology

  Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
• 
  Story Jan 06, 2015 From Our Labs

  Can we edit our genes to fight disease?

• 
  Story Jan 06, 2015 From Our Labs

  Rebuilding blood

  Why are some sickle cell disease patients protected from the disease? Learn about our biomedical research in the field.